Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BOLD vs EDGE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BOLD Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 6–2 Matrix Metrics)

BOLD Overall Winner 6-Pillar Tally: BOLD 2 – 1 EDGE (3 Tie) Matrix Metrics: BOLD 6 – 2 EDGE

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) is the stronger overall head-to-head candidate over EDGE (EDGE) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). BOLD carries a Unified Composite Score of 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin), whereas EDGE carries 43.7/100 (HOLD) at $46.01 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While EDGE currently prints a higher short-term Unified Composite Score (43.7/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile EDGE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BOLD vs EDGE
BOLD NASDAQ Head-to-Head Winner
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52
EDGE US Equity
EDGE
Institutional Equity
$46.01
-4.8% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.98β · 27% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 28.0 Fund 48.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.9%), weak momentum, RSI 24
RSI-14: 24.4 · SMA20: $50.70 · SMA50: $51.58

6-Pillar Scorecard Institutional Category Breakdown (BOLD 2 – 1 EDGE)

Columns: Metric · BOLD · EDGE
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BOLD
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $56.2M N/A
3. Profitability & Quality BOLD
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -64.6% N/A
4. Balance Sheet & Cash Flow EDGE
Cash Generation (TTM) -$48M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Debt (0.56x D/E) N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BOLD (6) vs EDGE (2)
Institutional Metric BOLD EDGE Criterion Row Edge
Market Capitalization
Scale
$56.2M N/A Larger Scale BOLD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth BOLD
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin BOLD
Net Profit Margin
Profitability
0.0% N/A Higher Margin BOLD
Return on Equity (ROE)
Capital Efficiency
-64.6% N/A Higher ROE BOLD
52-Week Range Position
Momentum
62% ($1–$3) 35% ($42–$53) Stronger Trend BOLD
Beta / 30D Volatility
Risk Regime
-0.08β · 28% Vol 0.98β · 27% Vol Lower Realized Risk EDGE
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 43.7 / 100 (HOLD) Higher Composite EDGE
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$48M ($31M Net Debt (0.56x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BOLD +6.55 pp
BOLD: -4.92% · EDGE: -11.47%
3M Horizon EDGE +10.82 pp
BOLD: -21.62% · EDGE: -10.8%
6M Horizon BOLD +67.01 pp
BOLD: +61.11% · EDGE: -5.9%
1Y Horizon BOLD +95.64 pp
BOLD: +101.74% · EDGE: +6.1%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs EDGE. Trailing 12-month operating profitability (BOLD 0.0% vs EDGE N/A) and valuation multiples (BOLD N/M vs EDGE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M
EDGE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EDGE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EDGE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EDGE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BOLD vs EDGE Key Questions & Quantitative Answers

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) is the stronger overall head-to-head candidate over EDGE (EDGE) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). BOLD carries a Unified Composite Score of 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin), whereas EDGE carries 43.7/100 (HOLD) at $46.01 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While EDGE currently prints a higher short-term Unified Composite Score (43.7/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile EDGE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BOLD leads the Growth & Scale pillar: BOLD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EDGE at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BOLD generates N/A in USD-normalized revenue versus N/A for EDGE. In operating R&D and SG&A reinvestment, BOLD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDGE.

BOLD and EDGE trade at balanced relative valuation multiples. BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EDGE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BOLD (-64.6% ROE) versus EDGE (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk). By comparison, EDGE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.